Skip to main content
Premium Trial:

Request an Annual Quote

OrigiMed, Partners Launch China-Focused Cancer Genetics Initiative

NEW YORK (GenomeWeb) — Precision medicine firm OrigiMed said today that it has launched a new initiative to create a cancer genetics database specific to the Chinese population.

The project — called the Special Chinese Big Data Platform for Cancer Genomics Informatics — aims to gather data on about 5,000 Chinese cancer patients to help identify the genetic drivers of the disease, as well as gather information on genes that contribute to metastasis, disease relapse, drug efficacy, and toxicity. According to Shanghai-based OrigiMed, these data will facilitate cancer research, and help clinicians diagnose patients and develop personalized treatment regimens.

In addition to OrigiMed, lead members of the initiative include the Beijing Xisike Clinical Oncology Research Foundation and the East Clinical Center of Ontology.

Nearly 40 hospitals are expected to participate in the effort, to which OrigiMed will contribute whole-exome sequencing data from more than 2,000 patients with various cancer types, sequencing data from around 450 cancer-related genes, and targeted clinical treatment plans.

Additional details were not disclosed.

Earlier this year, OrigiMed partnered with Illumina to develop next-generation sequencing-based cancer assays.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.